Cynapsus Therapeutics to Present at Two Upcoming Healthcare Conferences
September 03, 2015 16:00 ET
|
Cynapsus Therapeutics Inc.
TORONTO, Sept. 3, 2015 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc. (NASDAQ:CYNA) (TSX:CTH) today announced that its President and CEO, Anthony Giovinazzo, will present a corporate overview at the...
Cynapsus Therapeutics Enrolls First Patient in Pivotal Phase 3 Safety Study of APL-130277 for the Treatment of OFF Episodes in Patients With Parkinson's Disease
September 02, 2015 16:00 ET
|
Cynapsus Therapeutics Inc.
TORONTO, Sept. 2, 2015 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc. (NASDAQ:CYNA) (TSX:CTH) (the "Company") today announced enrollment of the first patient in the CTH-301 clinical trial, a pivotal...
Cynapsus Therapeutics Inc. : Announces Proposed Public Offering in the United States, Listing on NASDAQ and Share Consolidation
May 15, 2015 17:33 ET
|
Cynapsus Therapeutics Inc.
TORONTO, May 15, 2015 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc. (TSX: CTH) (OTCQX: CYNAF) announced today the filing of a registration statement with the US Securities and Exchange Commission...
Cynapsus Therapeutics Inc. : Reports First Quarter 2015 Financial Results and Recent Developments
May 08, 2015 16:54 ET
|
Cynapsus Therapeutics Inc.
TORONTO, May 8, 2015 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc. (TSX: CTH) (OTCQX: CYNAF), a specialty Central Nervous System (CNS) pharmaceutical company developing and preparing to commercialize...